| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Pawan K Singal | |
| Davinder S Jassal | |||
| Jonathan R Walker | |||
| P2860 | cites work | Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 | ||
| Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility | Q28239961 | ||
| Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy | Q28593656 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition | Q33263478 | ||
| Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies | Q33334742 | ||
| Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. | Q33427353 | ||
| Epidermal growth factor receptors: critical mediators of multiple receptor pathways | Q33597368 | ||
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 | ||
| The role of radiation therapy for primary breast cancer | Q33779190 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| Overexpression of ErbB2 in cancer and ErbB2-targeting strategies | Q33931164 | ||
| New strategies for managing metastatic breast cancer. | Q33942787 | ||
| Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. | Q34173142 | ||
| Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy | Q34429785 | ||
| Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. | Q34492647 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| Estimating the world cancer burden: Globocan 2000. | Q34518922 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy | Q34739645 | ||
| Adjuvant trastuzumab therapy for HER2-positive breast cancer | Q34817097 | ||
| Essential roles of Her2/erbB2 in cardiac development and function | Q35641803 | ||
| Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer | Q35792244 | ||
| Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy | Q36126521 | ||
| Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer | Q36441450 | ||
| Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy | Q36462641 | ||
| Herceptin (trastuzumab): adjuvant and neoadjuvant trials. | Q36533209 | ||
| Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management | Q36828128 | ||
| Cancer in Canada in 2008 | Q36972398 | ||
| Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when | Q37074153 | ||
| Sentinel lymphadenectomy in breast cancer | Q37084344 | ||
| Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring | Q37123487 | ||
| Cardiotoxicity profile of trastuzumab | Q37165488 | ||
| Trastuzumab-induced cardiomyopathy. | Q37178421 | ||
| Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). | Q37379904 | ||
| Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? | Q37471532 | ||
| FISH detection of HER-2/neu oncogene amplification in early onset breast cancer | Q38479141 | ||
| Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy | Q39467426 | ||
| Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. | Q40866492 | ||
| EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling | Q41737540 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways | Q43124366 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial | Q43610373 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol | Q45068575 | ||
| Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy | Q45175895 | ||
| Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer | Q45854680 | ||
| Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. | Q46037818 | ||
| Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy | Q46096452 | ||
| Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). | Q46295115 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Prediction of pathogenic mutations in patients with early-onset breast cancer by family history | Q57266776 | ||
| Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study | Q57695765 | ||
| Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy | Q73117839 | ||
| Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu | Q73174660 | ||
| A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization | Q74693294 | ||
| Doxorubicin-induced cardiomyopathy | Q77323607 | ||
| Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience | Q80112164 | ||
| Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment | Q81419131 | ||
| Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity | Q81698731 | ||
| Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial | Q83209550 | ||
| P433 | issue | 3 | |
| P921 | main subject | heart failure | Q181754 |
| trastuzumab | Q412616 | ||
| P304 | page(s) | e62-7 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Experimental & Clinical Cardiology | Q5421099 |
| P1476 | title | The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure | |
| P478 | volume | 14 |
Search more.